Table 6.

Multivariate analysis of overall survival from the initiation of AMR therapy

	OS
Variables	Hazard ratio	95% CI	P‐value
PS (0 vs.1,2)	2.57	1.23–5.36	0.01
Stage (IIIA, IIIB vs. IV)	3.42	0.95–12.28	0.06
EGFR mutation status (mutation vs. wild‐type, unknown)	1.44	0.63–3.31	0.39
Number of regimens before AMR (<3 vs. ≥ 3)	1.07	0.51–2.25	0.86
Response to AMR (PR vs. SD, PD)	3.58	0.94–13.54	0.06
topoisomerase‐II (low vs. high)	2.88	1.23–6.76	0.01

AMR, amrubicin; HR, hazard ratio; OS, overall survival; CI, confidence interval; CR, complete response; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.